Preservation of renal function: The spectrum of effects by calcium-channel blockers

Nephrology Dialysis Transplantation

Volumn 12, Issue 11, 1997, Pages 2244-2250

  Tarif, N ^a   Bakris, G L ^a,b,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b RUSH UNIVERSITY   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Albuminuria; Calcium channel blockers; Glomerular filtration rate; Glomerulosclerosis; Hypertension; Proteinuria

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOOP DIURETIC AGENT; MATRIX PROTEIN; NIFEDIPINE; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; AUTOREGULATION; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; GLOMERULOPATHY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MEMBRANE PERMEABILITY; MESANGIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEINURIA; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; GLOMERULAR FILTRATION RATE; HOMEOSTASIS; HUMANS; KIDNEY;

EID: 0030665405     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.11.2244     Document Type: Review

References (62)

1. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762
2. Gaber L, Walton C, Brown S, Bakris, GL. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994; 46: 161-169
3. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of different antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43: 1210-1218
4. Ferder L, Daccordi H, Martello M, Panzalis M, Inserra F. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 9 [Suppl. 2]: II-237-II-242
5. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy: Kidney Int. 1996; 50: 1641-1650
6. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Calcium channel or beta blockade on progression of diabetic renal disease in African-Americans. Hypertension 1997; 29: 773-780
7. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-1974
8. Maki DD, Ma JZ, Louis TA, Kasiske BL. Effects of antihypertensive agents on the kidney. Arch Intern Med 1995; 155: 1073-1082
9. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2-15
10. Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 113: 987-988
11. Capewell S, Collier A, Matthews D et al. A trial of the calcium antagonist felodipine in hypertensive type II diabetic patients. Diabetic Med 1989: 6(9): 809-812
12. Bakris GL, Mehler P, Schrier R. Hypertension and diabetes. In: Schrier RW, Gottschalk CW (eds.) Diseases of the Kidney 6th ed. Little Brown and Company, 1996, pp.1455-1464
13. Hatov C, Pavlova M, Demetrakov D, Veleukov H, Bakalov B. The influence of nifedipine on renal function in patients with chronic renal disease at the initial stage of drug use. Ther Arch 1990; 297: 88-89
14. Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS. Parving HH. Differences between nisoldipine and lisinopril in GFRs and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997; 46: 481-487
15. Gilbert RE, Jerums G, Allen T, Hammond J, Cooper ME on behalf of the Diabetic Nephropathy Study Group. Effect of different antihypertensive agents on normotensive microalbuminuric patients with IDDM and NIDDM J Ant Soc Nephrol 1994; 5: 377 (abstract)
16. Bakris GL. Hypertension in diabetic patients: An overview of interventional studies to preserve renal function. Am J Hypertens, 1993; 6(4): 140S-147S
17. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invent 1995; 96: 793-800
18. Jyothirmayi GN, Reddi AS. Effect of diltiazem on glomerular heparan sulfate and albuminuria in diabetic rats. Hypertension 1993; 21: 795-802
19. Kvam FI, Iverson BM, Ofstad J. Autoregulation of glomerular capillary pressure in SHR during successive reduction of systemic blood pressure with antihypertensive agents. J Am Soc Nephrol 1996; 7: 1552 (abstract)
20. Anderson S, Rennke HG, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 1992; 41(4): 891-897
21. Picken M, Griffin K, Bakris GL, Bidani A. Comparative effects of four different calcium antagonists on progression of renal disease in a remnant kidney model. J Am Soc Nephrol 1996; 7: 1586 (abstract)
22. Bakris GL, Picken M, Griffin K, Bidani A. Effects of a fixed dose combination of either amlodipine, benazapril or their combination on glomerulosclerosis and proteinuria. J. Hypertension (in press)
23. Perna A, Remuzzi G. Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. Am J Kidney Dis 1996; 27(1): 34-4124
24. Perez-Reyes E, Schneider T. Molecular biology of calcium channels. Kidney Int 1995; 48: 1111-1124
25. Nayler WG. Calcium channels and their involvement in cardiovascular disease. Biochem Pharmacol 1992; 43(1): 39-46
26. Schwartz A. Molecular and cellular aspects of calcium channel antagonism. Am J Cardiol 1992; 70: 6F-8F
27. Walsh KB, Bryant SH, Schwartz A. Effect of calcium antagonist drugs on calcium currents in mammalian skeletal muscle fibers. J Pharmacol Exp Ther 1986; 236(2): 403-407
28. Finkel MS, Patterson RE, Roberts WC, Smith TD, Keiser HR. Calcium channel binding characteristics in the human heart. Am J Cardiol 1988; 62(17): 1281-1284
29. Walker BR Evidence for uneven distribution of L-type calcium channels in rat pulmonary circulation. Am J Physiol 1995; 269: H2051-H2056
30. Bakris GL. Calcium channel blockers: are they all created equally with regard to slowing progression of diabetic nephropathy? In: Epstein M (ed) Calcium Antagonists in Clinical Medicine 2nd ed. Hanley & Belfus, Philadelphia (in press)
31. Hebert LA, Bain RP, Verme D et al. for the Collaborative Study Group. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994; 46: 1688-1693
32. Kilaru P, Bakris GL. Microalbuminuria and progressive renal disease J Hum Hypertens 1994; 8: 809-817
33. Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens 1996; 7: 219-223
34. Cohen MP, Clements RS, Cohen JA, Shearman CW. Prevention of decline in renal function in the diabetic db/db mouse. Diabetologia 1996; 39(3): 270-274
35. Cohen MP, Hud E, Wu VY, Ziyadeh FN. Albumin modified by Amadori glucose adducts activates mesangial cell type IV collagen gene transcription. Mol Cell Biochem 1995; 151: 61-67
36. Cohen MP, Sharma K, Jin Y et al. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists: a novel treatment strategy. J Clin Invest 1995; 95: 2338-2345
37. Smith AC, Bakris GL. Differential effects of calcium channel blockers on albuminuria and glomerular permeability in NIDDM subjects with nephropathy: pilot results of a two year study. J Am Soc Nephrol. 1996; 7: 1364 (abstract)
38. Carmines PK, Fowler BC, Bell PD. Segmentally distinct effects of depolarization on intracellular [Ca2+] in renal arterioles. Am J Physiol 1993; 265: F677-F685
39. Bakris GL, Smith AC. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996; 125[3]: 201-203
40. Nakamura T, Takahashi T, Fukui M et al. Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 1995; 5(7): 1492-1497
41. Carmines PK. Segment-specific effect of chloride channel blockade on rat renal arteriolar contractile responses to angiotensin II. Am J Hypertens 1995; 8(1): 90-94
42. Imig JD, Passmore JC, Anderson GL, Jimenez AE. Chloride alters renal blood flow autoregulation in deoxycorticosteronetreated rats. J Lab Clin Med 1993; 121(4): 608-613
43. Bakris GL, Shaikh M. Calcium channel blockers and progression of renal disease: clinical studies put into perspective. J Nephrol 1996; 9(6): 263-265
44. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360
45. Harris M. Classification, diagnostic criteria, and screening for diabetes. Diabetes in America. 2nd ed. 1995. NIH Publication No. 95-1468
46. Lazarus JM, Bourgoignie JJ, Buckalew VM et al. for the MDRD Group. Achievement and safety of a low blood pressure goal in chronic renal disease: the modification of diet in renal disease study group. Hypertension 1997; 29: 641-650
47. Bakris GL. Is the level of arterial pressure reduction important for preservation of renal function? Nephrol Dialysis and Transpl 1996; 11: 2383-2384
48. National High Blood Pressure Education Program Working Group. 1995 update of the Working Group reports on chronic renal failure and renovascular hypertension. Arch Intern Med 1996; 156: 1938-1947
49. Parving HH, Smidt UM. Hommel E. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993; 22: 188-195
50. Parving HH, Tarnow L. Rossing P. Renal protection in diabetes: an emerging role for calcium antagonists. J Hypertens 1996; 14 [Suppl 4]: S21-S25
51. Zucchelli P, Auzccala A, Borghi M et al. Long term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-458
52. Estacio RO, Savage S, Nagel NJ, Schrier RW. Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes Trials. Controlled Clin Trials 1996; 17: 242-257
53. Wright JR, Kusek J, Toto R et al. for the AASK Pilot Study Investigators. Design and baseline characteristics of participants in the African American Study of Kidney Diseases and hypertension (AASK) Pilot Study. Controlled Clinical Trials 1996: 17: 3S-16S
54. Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-222
55. Bakris GL. Weir MR. Salt intake and reductions in arterial pressure and proteinuria: is there a direct link? Am J Hypertens 1996; 9: 200S-206S
56. Heeg JE, deJong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272-279
57. Furberg CD, Psaty BM, Meyer JV. Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331
58. Packer M, O'Connor CM, Ghali JK et al. for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect on amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996; 335: 1107-1114
59. Hartmann A, Lund K, Holdass H, Fauchald P, Reisaeter A, Berg KJ. Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerulonephritic patients. J Am Soc Nephrol 1994; 5: 1385-1390
60. Danish Verapamil Reinfarction Study Group. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II) Am J Cardiol 1990; 66(10): 779-785
61. Roberts R, Gibson RS. Prevention of reinfarction subsequent to non-Q-wave infarction. J Cardiovasc Pharmacol 1989; 13 [Suppl 1]: S36-46
62. Fischer-Hansen J, Hagerup L, Sigurd B et al. and the Danish Verapamil Infarction Trial (DAVIT) Study Group. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolopril versus trandolopril alone. Am J Cardiol 1997; 79: 738-741